CenterBook Partners LP Has $32.18 Million Stake in Regeneron Pharmaceuticals, Inc. $REGN

CenterBook Partners LP boosted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 10.9% during the third quarter, Holdings Channel reports. The institutional investor owned 57,223 shares of the biopharmaceutical company’s stock after purchasing an additional 5,632 shares during the quarter. Regeneron Pharmaceuticals comprises approximately 1.6% of CenterBook Partners LP’s portfolio, making the stock its 6th largest holding. CenterBook Partners LP’s holdings in Regeneron Pharmaceuticals were worth $32,175,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Salomon & Ludwin LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the third quarter valued at approximately $27,000. Migdal Insurance & Financial Holdings Ltd. bought a new stake in shares of Regeneron Pharmaceuticals in the second quarter worth $31,000. Traub Capital Management LLC acquired a new position in Regeneron Pharmaceuticals during the second quarter worth $38,000. E Fund Management Hong Kong Co. Ltd. grew its position in Regeneron Pharmaceuticals by 87.5% in the third quarter. E Fund Management Hong Kong Co. Ltd. now owns 75 shares of the biopharmaceutical company’s stock valued at $42,000 after purchasing an additional 35 shares in the last quarter. Finally, Berbice Capital Management LLC increased its stake in Regeneron Pharmaceuticals by 300.0% in the 2nd quarter. Berbice Capital Management LLC now owns 80 shares of the biopharmaceutical company’s stock valued at $42,000 after buying an additional 60 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Trading Down 1.2%

Shares of Regeneron Pharmaceuticals stock opened at $793.53 on Wednesday. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.13 and a quick ratio of 3.39. The business has a fifty day simple moving average of $766.18 and a two-hundred day simple moving average of $670.05. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $821.11. The company has a market capitalization of $83.89 billion, a price-to-earnings ratio of 19.09, a P/E/G ratio of 2.16 and a beta of 0.40.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Friday, January 30th. The biopharmaceutical company reported $11.44 EPS for the quarter, beating the consensus estimate of $10.74 by $0.70. The firm had revenue of $3.88 billion for the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. The company’s quarterly revenue was up 2.5% on a year-over-year basis. During the same period in the previous year, the company earned $12.07 earnings per share. Research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 5th. Shareholders of record on Friday, February 20th will be given a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a yield of 0.5%. This is a boost from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. The ex-dividend date is Friday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 8.47%.

Insiders Place Their Bets

In related news, SVP Jason Pitofsky sold 2,036 shares of the business’s stock in a transaction on Monday, February 9th. The stock was sold at an average price of $778.52, for a total value of $1,585,066.72. Following the completion of the sale, the senior vice president directly owned 4,272 shares in the company, valued at $3,325,837.44. The trade was a 32.28% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Bonnie L. Bassler sold 1,500 shares of the stock in a transaction on Wednesday, January 7th. The stock was sold at an average price of $800.00, for a total value of $1,200,000.00. Following the transaction, the director owned 1,703 shares in the company, valued at $1,362,400. The trade was a 46.83% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 3,636 shares of company stock worth $2,862,920 over the last three months. Insiders own 7.02% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have commented on REGN. Zacks Research cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, February 6th. Bank of America upgraded Regeneron Pharmaceuticals from an “underperform” rating to a “buy” rating and upped their target price for the stock from $627.00 to $860.00 in a report on Wednesday, January 7th. Wells Fargo & Company increased their price target on Regeneron Pharmaceuticals from $745.00 to $800.00 and gave the company an “equal weight” rating in a research report on Monday, February 2nd. Scotiabank raised their price target on Regeneron Pharmaceuticals from $650.00 to $770.00 and gave the company a “sector perform” rating in a research note on Monday, November 24th. Finally, BMO Capital Markets upped their price objective on Regeneron Pharmaceuticals from $725.00 to $850.00 and gave the stock an “outperform” rating in a research note on Thursday, December 4th. Two analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $793.81.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.